CRISM Therapeutics Corporation (LSE:CRTX) is advancing the development of its proprietary localized chemotherapy delivery platform, seeking to transform therapeutic outcomes for patients suffering from inoperable or recurrent solid tumors. Quoted on the AIM market of the London Stock Exchange, the clinical-stage biotechnology enterprise specializes …
4basebio PLC (LSE:4BB) has positioned itself at the forefront of the advanced biomanufacturing sector by scaling the commercial production of synthetic, enzyme-based DNA constructs for cell, gene, and mRNA therapeutics. The biotechnology enterprise manufactures proprietary synthetic DNA products, known as hpDNA™ and oeDNA™. These …
Abingdon Health plc (LSE:ABDX) has successfully transformed its operational business model from pandemic-related testing into an internationally recognised contract development and manufacturing organisation (CDMO) specializing in rapid lateral flow diagnostic tests. The York-headquartered company provides end-to-end technical services—from assay design and clinical validation through …
Allergy Therapeutics plc (LSE:AGY) has continued to advance its clinical pipeline of next-generation, short-course subcutaneous allergy immunotherapies while maintaining commercial distribution across European healthcare markets. The specialty pharmaceutical enterprise develops disease-modifying allergy vaccines. Its proprietary technologies include modified allergen extracts (allergoids) formulated with microcrystalline …
Advanced Medical Solutions Group plc (LSE:AMS) has delivered sustained commercial expansion across global hospital operating theatres by accelerating adoption of its advanced wound closure and surgical tissue repair technologies. The Cheshire-headquartered medical device manufacturer designs and manufactures tissue adhesives, surgical sutures, and biosurgical collagen …
AOTI, Inc. (LSE:AOTI) has accelerated the commercial expansion of its proprietary medical technology across international healthcare markets, addressing the critical clinical challenge of non-healing diabetic foot ulcers and chronic wounds. The US-incorporated medical technology company designs and manufactures its patented Topical Wound Oxygen (TWO2) …
Aptamer Group Plc (LSE:APTA) has prioritized the commercial conversion of its proprietary Optimer technology platform as a cost-effective synthetic alternative to traditional antibodies. The life sciences company engineers nucleic acid-based affinity binders for bioprocessing, diagnostic assays, and targeted therapeutics. While biological antibodies suffer from …
Arecor Therapeutics PLC (LSE:AREC) has implemented decisive corporate restructuring initiatives designed to protect balance sheet liquidity and focus operational resources on commercializing its proprietary Arestat™ biopharmaceutical technology. The Cambridge-based biopharmaceutical enterprise utilizes innovative formulation science to transform the stability, delivery, and convenience of complex …
AstraZeneca PLC (LSE:AZN) has maintained its position as a powerhouse of global biopharmaceutical innovation, delivering steady revenue expansion across its diversified commercial portfolio. The multinational biopharmaceutical enterprise discovers, develops, and commercialises innovative prescription medicines across five core disease areas: Oncology, Cardiovascular/Renal/Metabolism (CVRM), Respiratory & …
Bioventix Plc (LSE:BVXP) has reaffirmed its status as one of the most profitable, cash-generative biotechnology specialists on the London Stock Exchange. The company specializes in the creation and commercial supply of high-affinity sheep monoclonal antibodies (SMAs). These specialised antibodies are supplied to global clinical …